Presentation is loading. Please wait.

Presentation is loading. Please wait.

Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21)‏ by Anthony V. Moorman, Susan.

Published byCharlotte Anderson Modified over 6 years ago

Similar presentations

Presentation on theme: "Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21)‏ by Anthony V. Moorman, Susan."— Presentation transcript:

1 Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21)‏ by Anthony V. Moorman, Susan M. Richards, Hazel M. Robinson, Jon C. Strefford, Brenda E. S. Gibson, Sally E. Kinsey, Tim O. B. Eden, Ajay J. Vora, Christopher D. Mitchell, and Christine J. Harrison Blood Volume 109(6): March 15, 2007 ©2007 by American Society of Hematology

2 EFS of patients treated on UK MRC ALL97 by cytogenetic subgroup
EFS of patients treated on UK MRC ALL97 by cytogenetic subgroup. iAMP21 indicates intrachromosomal amplification of chromosome 21q; t(12;21), t(12;21)(p13;q22)/ETV6-RUNX1; HeH, high hyperdiploidy (51-65 chromosomes); t(9;22), t(9;22)(q34;q11)/BCR-ABL; 11q23... EFS of patients treated on UK MRC ALL97 by cytogenetic subgroup. iAMP21 indicates intrachromosomal amplification of chromosome 21q; t(12;21), t(12;21)(p13;q22)/ETV6-RUNX1; HeH, high hyperdiploidy (51-65 chromosomes); t(9;22), t(9;22)(q34;q11)/BCR-ABL; 11q23, 11q23/MLL translocation; less than 40 chromosomes (chrs), near-haploidy (23-29 chromosomes), or low hypodiploidy (30-39 chromosomes); and other, all other patients. Anthony V. Moorman et al. Blood 2007;109: ©2007 by American Society of Hematology

Download ppt "Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21)‏ by Anthony V. Moorman, Susan."

Similar presentations

Pharmacogenetics of outcome in children with acute lymphoblastic leukemia by Jose Claudio C. Rocha, Cheng Cheng, Wei Liu, Shinji Kishi, Soma Das, Edwin.

Pharmacogenetics of outcome in children with acute lymphoblastic leukemia by Jose Claudio C. Rocha, Cheng Cheng, Wei Liu, Shinji Kishi, Soma Das, Edwin.
Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor.

Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor.
Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group by Phoenix.

Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group by Phoenix.
UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.
Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? by Ching-Hon Pui, Charles G. Mullighan, William E. Evans, and Mary.

Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? by Ching-Hon Pui, Charles G. Mullighan, William E. Evans, and Mary.
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia by Klaus H. Metzeler, Tobias Herold, Maja Rothenberg-Thurley, Susanne.

Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia by Klaus H. Metzeler, Tobias Herold, Maja Rothenberg-Thurley, Susanne.
Ingegerd Ivanov Öfverholm, MD, PhD

Ingegerd Ivanov Öfverholm, MD, PhD
Central venous line–related thrombosis in children: association with central venous line location and insertion technique by Christoph Male, Peter Chait,

Central venous line–related thrombosis in children: association with central venous line location and insertion technique by Christoph Male, Peter Chait,
What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of.

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of.
Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,

Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,
Higher Frequency of Glutathione S-Transferase Deletions in Black Children With Acute Lymphoblastic Leukemia by Chun-Lin Chen, Qing Liu, Ching-Hon Pui,

Higher Frequency of Glutathione S-Transferase Deletions in Black Children With Acute Lymphoblastic Leukemia by Chun-Lin Chen, Qing Liu, Ching-Hon Pui,
Immunosurveillance of Alglucerase Enzyme Therapy for Gaucher Patients: Induction of Humoral Tolerance in Seroconverted Patients After Repeat Administration.

Immunosurveillance of Alglucerase Enzyme Therapy for Gaucher Patients: Induction of Humoral Tolerance in Seroconverted Patients After Repeat Administration.
Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology.

Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology.
Clonal origins of relapse in ETV6-RUNX1 acute lymphoblastic leukemia

Clonal origins of relapse in ETV6-RUNX1 acute lymphoblastic leukemia
Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic.

Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic.
Retroviral and Chemical Mutagenesis Identifies Pax5 as a Tumor Suppressor in B-Progenitor Acute Lymphoblastic Leukemia by Jinjun Dang, Charles G Mullighan,

Retroviral and Chemical Mutagenesis Identifies Pax5 as a Tumor Suppressor in B-Progenitor Acute Lymphoblastic Leukemia by Jinjun Dang, Charles G Mullighan,
Outcomes in Patients with Chronic Myeloid Leukemia (CML) Who Are Treated with Imatinib As Front Line Therapy by Kendra L. Sweet, Najla H Al Ali, Jeffrey.

Outcomes in Patients with Chronic Myeloid Leukemia (CML) Who Are Treated with Imatinib As Front Line Therapy by Kendra L. Sweet, Najla H Al Ali, Jeffrey.
Reduced tumor load in peripheral blood after treatment with G-CSF and chemotherapy in children with tumors of the Ewing sarcoma family but not neuroblastoma.

Reduced tumor load in peripheral blood after treatment with G-CSF and chemotherapy in children with tumors of the Ewing sarcoma family but not neuroblastoma.

Similar presentations

Ads by Google